Ruining Bio
Jiading
About Ruining Bio
Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolization, and anti-tumor drugs. Ruining Bio brings together various professionals in materials, chemistry, biomedical engineering, and clinical medicine.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Total funding: $38.8M
- Funding stage: Late Stage Venture
- Last round: Series C (Feb 2026)
- Website: reunionbiotech.com
Industries & Categories
Medical, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/ruining-bio-66898 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.